TheraRadar
← Back
Data updated: Sep 20, 2026

ONESOURCE

Generics

ONESOURCE is a generic drug manufacturer focused on Immunology, Neurology.

2010
Since
15
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ONESOURCE's Key Drugs

ONESOURCE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ONESOURCE's Recent FDA Approvals

New NDA/BLA approvals for ONESOURCE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ONESOURCE's Therapeutic Areas

ONESOURCE's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 75%
3 drugs
Neurology 25%
1 drugs

ONESOURCE's Top Competitors

ONESOURCE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ONESOURCE Pipeline Snapshot

Active clinical trials for ONESOURCE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling